As the COVID-19 pandemic swept across the globe, people everywhere have raced to respond. The Luminex team has been working around the clock on much-needed molecular diagnostic assays for the SARS-CoV-2 virus, two of which recently received Emergency Use Authorization from the FDA.

Why not focus on one assay instead? As we see it, labs around the world need as many types of diagnostic tests as possible to address this pandemic, and it is crucial to get these new tests up and running quickly. Many can’t spare the time it would take to evaluate and install an entirely new diagnostic platform.

That’s why we developed assays for two of our most popular platforms, which are already in use in labs all around the world. The ® CoV Extended Panel (EUA-IVD)” href=”https://www.luminexcorp.com/?wpdmdl=40261″ target=”_blank” rel=”noopener noreferrer”>NxTAG^® CoV Extended Panel, which is a high-throughput, scalable, cost-effective option for detecting SARS-CoV-2 in up to 96 samples in approximately four hours. The NxTAG CoV Extended Panel, which can be run on our compact MAGPIX^® System, can also be used in parallel with the